Zimmer Biomet Holdings (ZBH) Stock Forecast & Price Target

Compare

1,072 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZBH Analyst Ratings

Hold

5 Buy

12 Hold

2 Sell

Based on 19 analysts giving stock ratings to

Zimmer

Biomet Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZBH Stock 12 Month Forecast

Average Price Target

$103.38

▲(16.07% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Zimmer Biomet Holdings in the last 3 months. The average price target is $103.38 with a high forecast of $130.00 and a low forecast of $88.00. The average price target represents a 16.07% change from the last price of $89.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"87":"$87","98":"$98","109":"$109","120":"$120","131":"$131"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$88.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[87,98,109,120,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.56,102.82461538461538,105.08923076923077,107.35384615384615,109.61846153846155,111.88307692307693,114.14769230769231,116.41230769230769,118.67692307692307,120.94153846153847,123.20615384615385,125.47076923076924,127.73538461538462,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.56,100.77692307692308,100.99384615384615,101.21076923076923,101.42769230769231,101.64461538461538,101.86153846153846,102.07846153846154,102.29538461538462,102.51230769230769,102.72923076923077,102.94615384615385,103.16307692307691,{"y":103.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.56,99.59384615384616,98.62769230769231,97.66153846153847,96.69538461538461,95.72923076923077,94.76307692307692,93.79692307692308,92.83076923076923,91.86461538461539,90.89846153846153,89.93230769230769,88.96615384615384,{"y":88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$130.00

Average Price Target$103.38

Lowest Price Target$88.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Newitter

Truist Financial

―

Hold

―

Reiterated

11/17/25

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Zimmer Biomet Holdings (NYSE: ZBH) and Hinge Health, Inc. Class A (NYSE: HNGE)

Travis Steed

Bank of America Securities

$110→$100

Hold

12.27%

Upside

Reiterated

11/10/25

Zimmer Biomet Holdings (ZBH) Gets a Hold from Bank of America SecuritiesWe maintain our Neutral rating on ZBH as we see it difficult for ZBH to accelerate growth.

Caitlin Cronin

Canaccord Genuity

$101→$93

Hold

4.41%

Upside

Reiterated

11/10/25

Zimmer Biomet price target lowered to $93 from $101 at CanaccordZimmer Biomet price target lowered to $93 from $101 at Canaccord

Jeff Johnson

Robert W. Baird

$125→$117

Buy

31.36%

Upside

Reiterated

11/06/25

Zimmer Biomet price target lowered to $117 from $125 at BairdZimmer Biomet price target lowered to $117 from $125 at Baird

Robbie Marcus

J.P. Morgan

$115→$100

Hold

12.27%

Upside

Downgraded

11/06/25

Zimmer Biomet downgraded to Neutral from Overweight at JPMorganZimmer Biomet downgraded to Neutral from Overweight at JPMorgan

Danielle Antalffy

UBS

$96→$88

Sell

-1.20%

Downside

Reiterated

11/06/25

UBS Remains a Sell on Zimmer Biomet Holdings (ZBH)

Lila Implantra

TR | OpenAI - 4o

$112→$117

Buy

31.36%

Upside

Reiterated

11/06/25

AI Generated ArticleAI Generated Article

Matt Miksic

Barclays

$105

Sell

17.88%

Upside

Reiterated

11/05/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Kymera Therapeutics (NASDAQ: KYMR) and Zimmer Biomet Holdings (NYSE: ZBH)

Larry Biegelsen

Wells Fargo

$93

Hold

4.41%

Upside

Initiated

11/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Exagen (NASDAQ: XGN), Zimmer Biomet Holdings (NYSE: ZBH) and Pelthos Therapeutics (NYSE MKT: PTHS)ZBH: Resuming Coverage at Equal Weight; $93 Price Target; Waiting for Better Execution (11/5)

Shagun Singh Chadha

RBC Capital

$111→$101

Buy

13.39%

Upside

Reiterated

11/05/25

RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)

David Roman

Goldman Sachs

$106→$97

Hold

8.90%

Upside

Reiterated

11/05/25

Zimmer Biomet price target lowered to $97 from $106 at Goldman SachsZimmer Biomet price target lowered to $97 from $106 at Goldman Sachs

Rick Wise

Stifel Nicolaus

$118→$110

Buy

23.50%

Upside

Reiterated

11/05/25

Zimmer Biomet Holdings: Strong Innovation Pipeline and Financial Health Justify Buy Rating Despite Recent Challenges

Josh Jennings

TD Cowen

$104→$99

Hold

11.15%

Upside

Reiterated

11/05/25

Zimmer Biomet Holdings: Mixed Q3 Performance and Narrowed Guidance Justify Hold Rating6:51 PM Zimmer Biomet Holdings (NYSE: ZBH) Hold (2) ESG $99.00 (Prior $104.00) Q3 US Report THE TD COWEN INSIGHT Q3 sales nearly matched the Street target, at $2.00B vs $2.01B, while EPS beat by $0.03, at $1.90 vs $1.87. US organic sales growth was 5.6%, though this strength was partly offset by weakness in Latin America, emerging markets in Europe and non-core businesses. ZBH narrowed its full-year guidance for organic sales growth, to 3.5- 4.0% from 3.5-4.5%, and maintained its EPS guidance of $8.10-$8.30. The Q3 Sales Performance Was Mixed: Q3 revenue was $2.00B, up 9.7% on a reported basis, 8.6% on a CC basis and 5.0% on an organic basis.

Michael Matson

Needham

―

Hold

―

Reiterated

11/05/25

Zimmer Biomet Holdings: Hold Rating Amid Revenue Miss and Market Share Decline

Ryan Zimmerman

BTIG

$122→$112

Buy

25.74%

Upside

Reiterated

11/05/25

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (NYSE: ZBH), ImmunityBio (NASDAQ: IBRX) and Geron (NASDAQ: GERN)We maintain our Buy but lower our PT to $112 (from $122) following disappointing 3Q25 results.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Newitter

Truist Financial

―

Hold

―

Reiterated

11/17/25

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Zimmer Biomet Holdings (NYSE: ZBH) and Hinge Health, Inc. Class A (NYSE: HNGE)

Travis Steed

Bank of America Securities

$110→$100

Hold

12.27%

Upside

Reiterated

11/10/25

Zimmer Biomet Holdings (ZBH) Gets a Hold from Bank of America SecuritiesWe maintain our Neutral rating on ZBH as we see it difficult for ZBH to accelerate growth.

Caitlin Cronin

Canaccord Genuity

$101→$93

Hold

4.41%

Upside

Reiterated

11/10/25

Zimmer Biomet price target lowered to $93 from $101 at CanaccordZimmer Biomet price target lowered to $93 from $101 at Canaccord

Jeff Johnson

Robert W. Baird

$125→$117

Buy

31.36%

Upside

Reiterated

11/06/25

Zimmer Biomet price target lowered to $117 from $125 at BairdZimmer Biomet price target lowered to $117 from $125 at Baird

Robbie Marcus

J.P. Morgan

$115→$100

Hold

12.27%

Upside

Downgraded

11/06/25

Zimmer Biomet downgraded to Neutral from Overweight at JPMorganZimmer Biomet downgraded to Neutral from Overweight at JPMorgan

Danielle Antalffy

UBS

$96→$88

Sell

-1.20%

Downside

Reiterated

11/06/25

UBS Remains a Sell on Zimmer Biomet Holdings (ZBH)

Lila Implantra

TR | OpenAI - 4o

$112→$117

Buy

31.36%

Upside

Reiterated

11/06/25

AI Generated ArticleAI Generated Article

Matt Miksic

Barclays

$105

Sell

17.88%

Upside

Reiterated

11/05/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Kymera Therapeutics (NASDAQ: KYMR) and Zimmer Biomet Holdings (NYSE: ZBH)

Larry Biegelsen

Wells Fargo

$93

Hold

4.41%

Upside

Initiated

11/05/25

Shagun Singh Chadha

RBC Capital

$111→$101

Buy

13.39%

Upside

Reiterated

11/05/25

RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)

David Roman

Goldman Sachs

$106→$97

Hold

8.90%

Upside

Reiterated

11/05/25

Zimmer Biomet price target lowered to $97 from $106 at Goldman SachsZimmer Biomet price target lowered to $97 from $106 at Goldman Sachs

Rick Wise

Stifel Nicolaus

$118→$110

Buy

23.50%

Upside

Reiterated

11/05/25

Zimmer Biomet Holdings: Strong Innovation Pipeline and Financial Health Justify Buy Rating Despite Recent Challenges

Josh Jennings

TD Cowen

$104→$99

Hold

11.15%

Upside

Reiterated

11/05/25

Michael Matson

Needham

―

Hold

―

Reiterated

11/05/25

Zimmer Biomet Holdings: Hold Rating Amid Revenue Miss and Market Share Decline

Ryan Zimmerman

BTIG

$122→$112

Buy

25.74%

Upside

Reiterated

11/05/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zimmer Biomet Holdings

1 Month

xxx

Success Rate

14/24 ratings generated profit

Average Return

+0.58%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +0.58% per trade.

3 Months

xxx

Success Rate

15/31 ratings generated profit

Average Return

+0.02%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 48.39% of your transactions generating a profit, with an average return of +0.02% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

16/31 ratings generated profit

Average Return

+3.55%

reiterated a buy rating 17 days ago

Copying Rick Wise's trades and holding each position for 1 Year would result in 51.61% of your transactions generating a profit, with an average return of +3.55% per trade.

2 Years

xxx

Success Rate

10/24 ratings generated profit

Average Return

-9.04%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 41.67% of your transactions generating a profit, with an average return of -9.04% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZBH Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZBH has received 16 Buy Ratings, 17 Hold Ratings, and 3 Sell Ratings. ZBH average Analyst price target in the past 3 months is 103.38.

Each month's total comprises the sum of three months' worth of ratings.

ZBH Financial Forecast

ZBH Earnings Forecast

Next quarter’s earnings estimate for ZBH is $2.40 with a range of $2.35 to $2.46. The previous quarter’s EPS was $1.90. ZBH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ZBH has Performed in-line its overall industry.

ZBH Sales Forecast

Next quarter’s sales forecast for ZBH is $2.22B with a range of $2.21B to $2.24B. The previous quarter’s sales results were $2.00B. ZBH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ZBH has Performed in-line its overall industry.

ZBH Stock Forecast FAQ

What is ZBH’s average 12-month price target, according to analysts?

Based on analyst ratings, Zimmer Biomet Holdings’s 12-month average price target is 103.38.

What is ZBH’s upside potential, based on the analysts’ average price target?

Zimmer Biomet Holdings has 16.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZBH a Buy, Sell or Hold?

Zimmer Biomet Holdings has a consensus rating of Hold which is based on 5 buy ratings, 12 hold ratings and 2 sell ratings.

What is Zimmer Biomet Holdings’s price target?

The average price target for Zimmer Biomet Holdings is 103.38. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $130.00 ,the lowest forecast is $88.00. The average price target represents 16.07% Increase from the current price of $89.07.

What do analysts say about Zimmer Biomet Holdings?

Zimmer Biomet Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of ZBH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Zimmer Biomet Holdings (ZBH) Stock Forecast & Price Target

ZBH Analyst Ratings

ZBH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zimmer Biomet Holdings

ZBH Analyst Recommendation Trends

ZBH Financial Forecast

ZBH Earnings Forecast

ZBH Sales Forecast

ZBH Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts